Medovate and JEB Technologies merge into one medical device company

Medovate and JEB Technologies will combine under the Medovate name by Sept. 21, 2026, creating a single business that spans device design, manufacturing, regulatory approval and international commercialization. The move expands the Suffolk-based group’s reach after two years of collaboration and sets up new product launches in 2027 and 2028.

Why it matters: - The combined company will give clinicians, innovators and medical technology firms one route from device concept to manufacturing and global launch. - Medovate will also add contract manufacturing services for companies that need a development and production partner. - The merger expands a regional medical device business into a broader international platform for product development and commercialization.

What happened: - Medovate and JEB Technologies are becoming one company under the Medovate name. - The combined company will officially launch by 21 September 2026, alongside a new Medovate website. - The businesses are based in Suffolk, East Anglia, United Kingdom. - The move follows two years of close collaboration between the companies. - Their products have launched in more than 12 international markets, including the USA, Australia, New Zealand, the United Arab Emirates, Saudi Arabia and several European countries.

The details: - The expanded business will cover medical device design, development, manufacturing, regulatory approval, international launch and commercialization. - The new structure brings together teams, operations and expertise under one brand. - The combined company will operate as a single end-to-end medical device development and manufacturing business. - Medovate says the setup will help the business use combined resources more efficiently. - Craig Sturdy, International Distribution Manager at Medovate, said the merger brings together manufacturing expertise with development and commercial capability. - Stuart Thomson, Vice President of Business Development at Medovate, said the combination strengthens the company’s ability to deliver medical innovations that improve patient safety. - Thomson also said the company’s plans include new international product launches in 2027 and beyond. - The partnership has already helped streamline product development and manufacturing by putting both capabilities under one roof. - The teams have been able to develop and commercialize several products at the same time. - The companies have also promoted their products and services at international healthcare conferences and exhibitions. - The current portfolio includes SAFIRA®, a system designed to help improve safety during regional anaesthesia. - The portfolio also includes CamPROBE®, a simple and cost-effective solution intended to facilitate transperineal prostate biopsies under local anaesthetic. - Products in development include LumeVac and TransiCap.

Between the lines: - The merger formalizes a working relationship that already produced international launches and a shared commercial footprint. - Bringing development, manufacturing and distribution into one company can shorten timelines and reduce handoffs for medical device customers. - The company is positioning itself to compete as a full-service partner rather than only a device developer or manufacturer.

What's next: - Medovate plans to secure regulatory approval for a new medical device and launch it in the USA and Europe during 2027. - Additional products are expected to move toward regulatory approval and international launch in 2028. - The new website and unified brand launch are expected by 21 September 2026.